

H K E C L E H K L
C C C C C C C C C C C C
C C C C C C C C C C C C



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(P C)
(Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

13.0 (2) 13.10 G
K m I I rm
A I I rm
5 1
K

201 (Gr)
* (“Company”, b A “Group”).
b

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C

A
2 r. 201

A M. C M. F; C
M. G G C, M. C M. G M. P C M. K L C
C H C M. H J C, D. C M. L M C A D C M.

* F C C

1 IMPORTANT NOTICE

1.1 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.2 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.3 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

1.4 The Board of Directors of the Company has reviewed the financial statements of the Company for the reporting period, and the financial statements are true and accurate, and the financial statements are prepared in accordance with the applicable accounting standards and the Company's financial reporting policies.

2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

2.1 Major financial information of the group

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
Revenue (RMB million)	30,052,255 / 1.23	2,510,011 / 1.1	1.3
Profit attributable to equity holders of the parent (RMB million)	15,211,115	15,332,111 / 1.303	1.3
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Profit attributable to equity holders of the parent (N/A)	1,021,511 / 1.3	1,153,115	-0.1
	From the beginning of the year to the end of the Reporting Period (Jan - Mar)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar)	Year-on-year change (%)
Profit attributable to equity holders of the parent (RMB million)	2,511,215 / 1.1	2,055,511 / 1.2	2.2

3 SIGNIFICANT EVENTS

3.1 ...

✓ ^A ^A ...

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
...	2,07,121.20	1,37,300.25	147%	...
...	32,25,31.2	12,31,11.2	111%	...
Income Statement				
Items	Current Amount	Amount of the last period	Ratio of change	Reasons
	(Jan – Mar 2014)	(Jan – Mar 2013)		
...	1,55,03.3	1,12,50.5	138%	...
...	31,25,2.2	2,07,110.1	5%	...
...	1,55,01.3	32,51,2.2	-5%	...
...	1,01,1,1.2	25,200,01.1
...	1,030.05	1,030.3	-5%	...
...	2,11,...	1,030,...	5%	...
...	1,10,2.5	25,1,3.3	-52%	...

(3) 2/2011, m (r r r) r, r r m I r m * (上

Balance Sheet of the Company

31 M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Monetary assets	13,015,030.0	12,131,151.1
Accounts receivable		
Prepaid expenses		
Other receivables		
Inventory		
Investments	3,121,050	2,551,550
Fixed assets	1,522,220	1,522,220
Intangible assets	1,002,751	1,002,751
Other non-current assets	51,300	51,300
Other non-current assets		
Other non-current assets	1,000,000.00	2,500,000.00
Other non-current assets	3,300,201	3,020,220
Non-current assets:		
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets	5,253,350	5,300,550
Other non-current assets		
Other non-current assets	1,302,100	201,500
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets		
Other non-current assets	2,011,000	3,050,350
Other non-current assets		
G		
Other non-current assets		
Other non-current assets		
Other non-current assets	3,515,515	3,020,220
Other non-current assets	3,300,201	3,020,220
Other non-current assets	13,132,303	12,551,321

Balance Sheet of the Company (Continued)

31 M 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Trade payables	10,000,000.00	3,000,000.00
Other payables		
Accrued expenses		
Provisions		
Financial liabilities	5,500,000.00	1,000,000.00
Income tax payable	1,130,000.00	222,300.00
Dividend payable	10,220,000.00	1,355,500.00
Other current liabilities		
Current liabilities	37,050,000.00	10,577,800.00
Non-current liabilities:		
Trade payables	325,000,000.00	125,000,000.00
Other payables	1,052,310.00	1,033,120.00
Financial liabilities		
Provisions		
Income tax payable		
Other non-current liabilities		
Non-current liabilities	1,056,310.00	1,266,120.00
Equity attributable to the owners (or equity attributable to shareholders):		
Share capital (paid-up)	2,200,000.00	2,200,000.00
Reserves	3,720,200.00	3,712,100.00
Retained earnings		
Other equity		
Equity attributable to the owners	5,920,200.00	5,912,100.00
Other equity		
Other equity		
Other equity		
Other equity		
Other equity	1,052,310.00	1,033,120.00
Other equity	5,920,200.00	5,912,100.00
Other equity	13,132,310.00	12,550,920.00

m
A

Consolidated Income Statement

J 6 - M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I.	2,572,571	2,055,571
I	2,572,571	2,055,571
I		
r		
mm		
II.	2,520,530	1,235,173
I	1,550,333	1,125,055
I		
mm		
r		
m		
r		
r		
r		
A		
m		
r	1,333,222	1,027,211
A	502,312	107,844
m	31,252	2,071,101
A	2,315,773	7,321,000
A	1,220,312	13,222
G	1,550,133	32,512
I	1,111,772	2,520,011
I	2,330,215	13,371,171
r		
III.	5,070,233	3,011,355
I	1,100,055	1,030,333
I	3,312,770	2,071,333
I	55,133	550,055
IV.	5,500,233	5,270,325
I	2,111,333	1,030,333
I	727,055	12,333
I	13,173	5,200,271
G	1,270,771	1,070,333
V.		
(1)	0.1	0.1
(2)	0.1	0.1
VI.	1,107,255	25,373
III.	1,107,255	3,512
m	515,155	3,070,071
m	255,572	5,055,055

A

m J r m J

Income Statement of the Company

J 6 - M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I.		
A	52,510,115	20,200,502
	-3,102,011	1,203,322
A		
G		
I	2,102,221	2,111,151
I	2,002,511	3,523,211
II.	-1,023,311	2,550,311
	5,000.00	1,032.11
	2,000,000.00	5,111.21
I		
III.	-1,202,311	2,511,211
I	-1,202,311	2,511,211
(1)	-0.00	0.12
(2)	-0.00	0.12
I		5,211.50
II.	-1,202,311	2,511,011.52

Consolidated Statements of Cash Flows (Continued)

J 6 – M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
Interest on long-term debt	5,170.00	
Interest on short-term debt	5,170.00	
Proceeds from the issuance of long-term debt	1,525,150	1,700,000
Proceeds from the issuance of short-term debt		
Proceeds from the sale of equity	21,500	
Proceeds from the sale of property, plant, and equipment	2,203,320	1,700,000
Proceeds from the sale of investments	12,253,233	1,700,000
Proceeds from the sale of other assets	20,220,000	1,250,000
Interest on long-term debt	(1,000,000.00)	(51,250)
Interest on short-term debt	(1,300,000)	(25,000)
Proceeds from the sale of property, plant, and equipment	330,500	32,000
Proceeds from the sale of investments	(1,300,000)	(1,000,000)
IV. Effects of exchange rate fluctuations on cash and cash equivalents	(3,000,000.00)	(5,000,000)
V. Net increase of cash and cash equivalents	3,000,201.33	(55,721,320)
Cash and cash equivalents at the beginning of the period	2,120,300	1,150,000
VI. Closing balance of cash and cash equivalents	2,532,051.00	3,515,520

m
A

Statements of Cash Flows of the Company

J 6 - M 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		
	3,335,12.12	15,110.10
	3,335,12.12	15,110.10
	2,123.5	21,532.32
	155,10.2	1,215.5
	1,000.0	11,535.3
	50,510.0	1,133.30
	-1,012.0	-2,023.53
II. Cash flow generated from investing activities:		
	200,015	15,530.00
	50,000.00	3,232
	250,015	15,102.2
		5,500.00
	315,000,000.00	
	2,023,100.00	5,000.00
	3,2023,100.00	5,1550.00
	-3,125.15	-33,015.51

Statements of Cash Flows of the Company (Continued)

J 6 – M 2014

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
r r m r b		
r r m b r	50,000,000.00	
r r m b		
r r r	1, /, /, /, /, /	5, 5, /, /, /
b- r m	2, /, /, /, /, /	5, 5, /, /, /
r b m		
r r b, r r m	10, /, /, /, /, /	10, 500,000.00
r r	1, /, /, /, /, /	/02, /, /, /, /
b- r m	1, 5, /, /, /, /, /	0, /, /, /, /, /
r r m	3, /, /, /, /, /	-2, /, /, /, /, /
IV. Effects of exchange rate fluctuations on cash and cash equivalents	/, /, /, /, /	-5, /, /, /, /, /
V. Net increase of cash and cash equivalents	-15, /, /, /, /, /	-5, /, /, /, /, /
b	5 /, /, /, /, /	2, /, /, /, /, /
VI. Closing balance of cash and cash equivalents	50, /, /, /, /, /	1, /, /, /, /, /

m
A

* F 6 6 6